These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 21567034

  • 21. Chromosomal breakage correlates with delayed lethality in normal and ataxia telangiectasia cell lines treated with bleomycin.
    MacLeod RA, Buchheim T, Kaufmann M, Drexler HG.
    Mutat Res; 1996 Nov 11; 372(1):33-42. PubMed ID: 9003529
    [Abstract] [Full Text] [Related]

  • 22. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
    Xiang TX, Niemi R, Bummer P, Anderson BD.
    J Pharm Sci; 2003 Oct 11; 92(10):2027-39. PubMed ID: 14502542
    [Abstract] [Full Text] [Related]

  • 23. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov 11; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

  • 24. Modification of bleomycin-induced chromosome aberrations by hyperthermia and under energy depleting conditions in human peripheral lymphocytes.
    Weissenborn U, Obe G.
    Int J Radiat Biol; 1992 Sep 11; 62(3):289-96. PubMed ID: 1382108
    [Abstract] [Full Text] [Related]

  • 25. Schedule dependent variation in human lymphocyte sensitivity to bleomycin and repair of chromosomal aberrations in G2.
    Lefterov IM, Koldamova RP.
    Mutat Res; 1992 Dec 16; 284(2):195-204. PubMed ID: 1281270
    [Abstract] [Full Text] [Related]

  • 26. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
    Wong PP, Currie VE, Mackey RW, Krakoff IH, Tan CT, Burchenal JH, Young CW.
    Cancer Treat Rep; 1979 Aug 16; 63(8):1245-9. PubMed ID: 383291
    [Abstract] [Full Text] [Related]

  • 27. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
    Kreis W, Woodcock TM, Gordon CS, Krakoff IH.
    Cancer Treat Rep; 1977 Oct 16; 61(7):1347-53. PubMed ID: 589600
    [Abstract] [Full Text] [Related]

  • 28. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM, Rustum YM.
    Cancer Res; 1985 Dec 16; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [Abstract] [Full Text] [Related]

  • 29. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
    Mekras JA, Boothman DA, Greer SB.
    Cancer Res; 1985 Nov 16; 45(11 Pt 1):5270-80. PubMed ID: 2932216
    [Abstract] [Full Text] [Related]

  • 30. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
    Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ.
    Biochem Pharmacol; 2004 Feb 01; 67(3):503-11. PubMed ID: 15037202
    [Abstract] [Full Text] [Related]

  • 31. Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells.
    Minford J, Kerrigan D, Nichols M, Shackney S, Zwelling LA.
    Cancer Res; 1984 Dec 01; 44(12 Pt 1):5583-93. PubMed ID: 6208999
    [Abstract] [Full Text] [Related]

  • 32. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
    Takemura H, Urasaki Y, Yoshida A, Fukushima T, Ueda T.
    Cancer Res; 2001 Jan 01; 61(1):172-7. PubMed ID: 11196156
    [Abstract] [Full Text] [Related]

  • 33. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
    Danhauser LL, Rustum YM.
    Cancer Res; 1985 May 01; 45(5):2002-7. PubMed ID: 3986756
    [Abstract] [Full Text] [Related]

  • 34. Specificity of bleomycin-induced cytotoxic effects on ataxia telangiectasia lymphoid cell lines.
    Cohen MM, Simpson SJ, Pazos L.
    Cancer Res; 1981 May 01; 41(5):1817-23. PubMed ID: 6163529
    [Abstract] [Full Text] [Related]

  • 35. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
    Horber DH, Schott H, Schwendener RA.
    Br J Cancer; 1995 May 01; 71(5):957-62. PubMed ID: 7734320
    [Abstract] [Full Text] [Related]

  • 36. Bleomycin-induced chromosomal aberrations in Epstein-Barr virus-transformed human lymphoblastoid cells.
    Cardozo AG, Castrogiovanni DC, Bolzán AD.
    Mutat Res Genet Toxicol Environ Mutagen; 2024 Oct 01; 899():503823. PubMed ID: 39326941
    [Abstract] [Full Text] [Related]

  • 37. Metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA of human T-lymphoblastic cells (Molt-4).
    Townsend A, Leclerc JM, Dutschman G, Cooney D, Cheng YC.
    Cancer Res; 1985 Aug 01; 45(8):3522-8. PubMed ID: 2410096
    [Abstract] [Full Text] [Related]

  • 38. Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity.
    Honma Y, Onozuka Y, Okabe-Kado J, Kasukabe T, Hozumi M.
    Cancer Res; 1991 Sep 01; 51(17):4535-8. PubMed ID: 1873797
    [Abstract] [Full Text] [Related]

  • 39. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV, Avramis VI.
    Cancer Chemother Pharmacol; 1995 Sep 01; 35(3):191-9. PubMed ID: 7805176
    [Abstract] [Full Text] [Related]

  • 40. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
    Kong XB, Tong WP, Chou TC.
    Mol Pharmacol; 1991 Feb 01; 39(2):250-7. PubMed ID: 1705001
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.